EUCTR2019-003197-24-GB进行中（未招募）1 期
A Phase 2, Randomized, 3-Arm Parallel Group, Placebo and Active-Controlled Study of the Effect of PL8177 Administered via Subcutaneous Injection in Healthy Male Volunteers on Inflammatory Onset and Resolution - SCIO
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1. Healthy male participants on the Fitzpatrick scale of 1 to 3, between 18 and 45
- •years of age, inclusive, at screening.
- •2. Body mass index between 18.0 and 30.0 kg/m2, inclusive, with body weight not
- •less than 50 kg, at screening.
- •3. In good health, determined by no clinically significant findings from
- •medical/surgical history, physical examination, vital sign measurements, 12-lead
- •ECG, and clinical laboratory evaluations (congenital nonhemolytic
- •hyperbilirubinemia (e.g. Gilbert’s syndrome) is not acceptable at screening), as
- •assessed by the Investigator (or designee).
- •4. A 12-lead ECG consistent with normal cardiac conduction and function at screening, including; HR between 45 and 100 bpm, QTcF interval less than or equal to 450 ms , QRS interval <120 ms, PR interval <220 ms and morphology consistent with healthy cardiac conduction and function.
- •5. Has clinical chemistry, haematology, coagulation and complete urinalysis (fasted for at least 4 hours) results at screening within the reference range for the testing laboratory, unless the out of range results are deemed not clinically significant by the Investigator.
- •6. A male volunteer with sexual partners who could become pregnant must meet the following criteria:
- •a. Participants who are sexually active agree to use one of the accepted contraceptive regimens from first drug administration until 3 months (90 days) after the drug administration. An acceptable method of contraception includes one of the following; abstinence from vaginal intercourse, condom with spermicide or condom with intra-vaginally applied spermicide.
- •b. Male participants must agree to provide any requested information about the pregnancy should contraception fail and a pregnancy occurs within the 90 days after the drug administration.
- •c. Male participants subjects must agree to not donate sperm during the study and for 3 months (90 days) after receiving the last dose of study drug.
- •7. Able to comprehend and willing to sign an Informed Consent Form (ICF) and to abide by the study restrictions.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 45
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Significant history or clinical manifestation of any medical illness including (but not limited to); metabolic, dermatological, hepatic, renal, haematological, pulmonary, cardiovascular, coagulation disorder, lipid abnormality, gastrointestinal (GI), immunologic, neurological, respiratory, endocrine, psychiatric disorder, or infectious disease (including tuberculosis), any other current physical condition that the Investigator considers should exclude the participant, or that could interfere with the interpretation of the study results as determined by the Investigator (or designee).
- •2. Participants with significant history of or clinical manifestation of a dermatologic disorder, including but not limited to psoriasis, severe acne, seborrhoea, and eczema. Mild to moderate acne limited to the face, chest, and shoulders is acceptable. The skin of the forearms must not be affected.
- •3. Has any clinically significant physical examination finding, ECG abnormality, or clinically significant abnormal value for clinical chemistry, haematology, coagulation, or urinalysis at screening or any significant physical exam finding, clinically significant abnormal value for clinical chemistry, haematology or urinalysis at baseline, as determined by the Investigator.
- •4. Has any of the following:
- •a. Systolic blood pressure <90 mmHg or >140 mmHg at screening (measured in seated position)
- •b. Diastolic blood pressure of <50mmHg or >90 mmHg at screening
- •(measured in seated position)
- •c. Heart rate <45 bpm or >100 bpm
- •5. Currently suffers from clinically significant systemic allergic disease as determined by the Investigator, or has a history of significant drug allergies,
- •6. Current systemic infection.
- •7. History or current manifestation of herpes infection of the eye.
- •8. History or current manifestation of galactose or lactose intolerance or glucosegalactose malabsorption.
- •9. History or current manifestation of severe depression or manic-depression (bipolar disorder), or if any close family member (parent, sibling, or offspring) has had severe depression or manic-depression, steroid psychosis, emotional instability, or psychotic tendencies.
- •10. Receipt of any live vaccine within 30 days prior to screening or intent to receive any live vaccine within 90 days following completion of the study.
- •11. History of adverse reaction to corticosteroid, including fluid retention, alteration in glucose tolerance, elevation in blood pressure, behavioural and mood changes, increased appetite and weight gain.
- •12. History or presence of malignancy within the past 5 years with the exception of adequately treated localised skin cancer (basal cell or squamous cell carcinoma) which is allowed.
- •13. Personal history or family history of melanoma (for the purposes of this study family history is defined as history in first-degree relatives i.e. parents or siblings).
- •14. History of hyperplastic, dysplastic or atypical nevi.
- •15. Has had an acute or clinically significant illness as determined by the Investigator, within 30 days prior to Day 1, or has had a recent febrile illness with an abnormal body temperature within 72 hours before dosing on Day 1.
- •16. History of alcoholism or drug/chemical abuse within 2 years prior to screening.
- •17. Has a positive test for hepatitis B surface antigen, hepatitis C antibody, or human immunodeficiency virus (HIV) at screening or has been previously treated for hepatitis B, hepatitis C or HIV infection.
- •18. Participation in a clinical study invol
研究者
相似试验
尚未招募
3 期
Evaluation the efficacy and safety of Cetuximab bio-similar compared to Erbitux in the patients with head and neck squamous cell carcinoma.Head and Neck Squamous Cell Carcinoma (HNSCC).IRCT20190112042328N1Zistdaru Danesh Co. ®163
已完成
3 期
A Study to Evaluate and Compare the Efficacy and Safety of Mirabegron 25 mg ER tablet and 50 mg ER tablet with Tolterodine 4 mg ER tablet in Patients with Overactive Bladder.CTRI/2016/04/006790MSN Laboratories Private Limited312
招募中
3 期
Evaluation of immunogenicity and safety of the 13-valent pneumococcal vaccine (PneumoConj®- manufactured by Nivad Pharmed Salamat), compared to the 13-valent pneumococcal vaccine (Prevnar®- manufactured by Pfizer) as the reference product, in infants aged 8 ± 2 weeksOtitis media prevention / Pneumonia prevention.Pneumonia due to Streptococcus pneumoniaeIRCT20240626062259N1ivadPharmed Salamat company324
进行中（未招募）
不适用
A Phase III, randomized, parallel group, double-blind, placebo-controlled, multi-center study to assess the efficacy and safety of PGL4001 (ulipristal) versus placebo for pre-operative treatment of symptomatic uterine myomas - PGL4001 versus placebo in uterine myomasterine myoma are benign, monoclonal, hormone sensitive, smooth muscle tumors of the uterus. It is the most common tumor of the female reproductive tract in pre-menopausal women and mostly asymptomatic. When symptomatic, its cardinal symptoms are heavy uterine bleeding, anaemia, abdominal pressure, abdominal pain, urinary frequency and infertility. Myomas affect approximately 40% of women between 35 and 55 years.MedDRA version: 9.1Level: LLTClassification code 10046801Term: Uterine myomaEUCTR2008-001804-22-CZPregLem S.A.240
进行中（未招募）
不适用
A Phase III, randomized, parallel group, double-blind, placebo-controlled, multi-center study to assess the efficacy and safety of PGL4001 (ulipristal) versus placebo for pre-operative treatment of symptomatic uterine myomas - PGL4001 versus placebo in uterine myomasterine myoma are benign, monoclonal, hormone sensitive, smooth muscle tumors of the uterus. It is the most common tumor of the female reproductive tract in pre-menopausal women and mostly asymptomatic. When symptomatic, its cardinal symptoms are heavy uterine bleeding, anaemia, abdominal pressure, abdominal pain, urinary frequency and infertility. Myomas affect approximately 40% of women between 35 and 55 years.MedDRA version: 9.1Level: LLTClassification code 10046801Term: Uterine myomaEUCTR2008-001804-22-HUPregLem S.A.240